Posted by Michael Wonder on 14 Apr 2021
AstraZeneca’s COVID-19 vaccine: EMA to provide further context on risk of very rare blood clots with low blood platelets
14 April 2021 - EMA continues to monitor very rare blood clots with low blood platelets that occurred after vaccination with Vaxzevria (previously COVID-19 Vaccine AstraZeneca).
In line with a request from the EU’s Commissioner for Health and Food Safety following a meeting of EU Health Ministers, EMA is undertaking a review of vaccination data and data on disease epidemiology (including infection rates, hospitalisations, morbidity and mortality).
